Share |
 
     
     
 
Clinical Research

Investigator for Clinical trials and Drug Research:
-
Subinvestigator, A Randomized, Multicenter, Double-Blind, Placebo Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of Investigational drug in Subjects with Relapsing-Remitting Multiple Sclerosis
 
-
Subinvestigator, An international, randomized, double-blind, parallel-group, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of Investigational drug in subjects (≥ 16 to 70 years old) suffering from localization-related or generalized epilepsy
 
-
Subinvestigator, An Open label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of Investigational drug used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from epilepsy
 
-
Subinvestigator, Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with Investigational drug in patients with a history of ischaemic stroke or transient ischaemic stroke - The PERFORM study.
 
-
Subinvestigator, A Randomised, Double-blind, Placebo-controlled, Parallel-Group, Multicentre study to Evaluate the Efficacy, Safety, and Tolerability of Investigational drug as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-label Extension study
 
-
Subinvestigator, Effect of g-Secretase Inhibition on the Progression of Alzheimer's Disease.
 
-
Subinvestigator, A Phase III, double blind, placebo controlled randomized trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson's disease treated with a stable dose of a single dopamine agonist.
   
-
Subinvestigator, A Phase III, double blind, placebo controlled randomized trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as an add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine
   
-
Subinvestigator, A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, with Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the Cogstate Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients Randomized to Either Donepezil or Placebo